Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 10 2025
0mins
Source: Newsfilter
Appointment of Dr. Robert Wills: Alpha Cognition Inc. has appointed Dr. Robert Wills to its Board of Directors, effective April 7, 2025, bringing extensive experience in drug development and corporate strategy to support the launch of their Alzheimer's treatment, ZUNVEYL.
John Havens' Departure: John Havens will not seek re-election to the Board for 2025, after contributing since 2018; the company will begin searching for a new independent board member to fill his position.
Analyst Views on ACOG
Wall Street analysts forecast ACOG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACOG is 18.00 USD with a low forecast of 18.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.820
Low
18.00
Averages
18.00
High
18.00
Current: 5.820
Low
18.00
Averages
18.00
High
18.00
About ACOG
Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company's ZUNVEYL (benzgalantamine) product is a delayed release oral tablet formulation indicated for the treatment of mild to moderate dementia of the Alzheimer’s type in adults. Its pre-clinical development programs include ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mTBI; ALPHA-0602; ALPHA-0702 & ALPHA-0802 (Progranulin and Progranulin GEM’s) for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis or Lou Gehrig’s disease and spinal muscular atrophy, and ALPHA-1062 for the treatment of acute pancreatitis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
